Esaote North America Announces a Multi-Year Contract with Vizient

Summation

  • Esaote North America said the new agreement provides Vizient members access to contracts that offer increased savings on Esaote North America’s comprehensive Ultrasound product line and services, including the widely popular MyLabTM family portfolio.
  • “Our unique ultrasound portfolio is optimized for high performance in the most demanding clinical settings, covering a broad spectrum of clinical applications without compromising image quality or workflow efficiency,”.
  • Esaote North America is an internationally recognized leader that provides superior Ultrasound point-of-care solutions, Dedicated MRI systems, and Healthcare IT workflow solutions.

Esaote North America announces a multi-year contract with Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company, serving more than 50% of the nation’s acute care providers.

Esaote North America said the new agreement provides Vizient members access to contracts that offer increased savings on Esaote North America’s comprehensive Ultrasound product line and services, including the widely popular MyLabTM family portfolio.

“Our unique ultrasound portfolio is optimized for high performance in the most demanding clinical settings, covering a broad spectrum of clinical applications without compromising image quality or workflow efficiency,” said Robert Lewis, President and General Manager at Esaote North America.

Esaote North America is an internationally recognized leader that provides superior Ultrasound point-of-care solutions, Dedicated MRI systems, and Healthcare IT workflow solutions. Esaote’s founding philosophies continue to push the technological boundaries of the medical device industry, delivering cost-effective and eco-friendly diagnostic imaging solutions that meet customers’ needs worldwide.

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy